Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugene Sun

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|June 28, 2002
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infectionSharon Walmsley, Barry Bernstein, Martin King, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman, Andrew Zolopa, Diane Havlir, et al.
The Journal of Infectious Diseases|June 25, 2004
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patientsMartin S King, Barry M Bernstein, Sharon L Walmsley, et al.
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The Journal of Infectious Diseases|March 28, 2003
Determining the relative efficacy of highly active antiretroviral therapyMichael Louie, Christine Hogan, Michele Di Mascio, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant TuberculosisPauline Howell, Antonio Lombardi, William Brumskine, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patientsAnn Hsu, Jeffrey Isaacson, Scott Brun, et al.
Disasters|March 8, 2014
Health care system hazard vulnerability analysis: an assessment of all public hospitals in Abu DhabiSaleh Fares, Meg Femino, Assaad Sayah, et al.
The Journal of Infectious Diseases|January 15, 2004
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trialJoseph J Eron, Judith Feinberg, Harold A Kessler, et al.
Pharmaceutical Research|October 23, 2004
Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humansGondi N Kumar, Venkata K Jayanti, Marianne K Johnson, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|June 28, 2002
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infectionSharon Walmsley, Barry Bernstein, Martin King, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman, Andrew Zolopa, Diane Havlir, et al.
The Journal of Infectious Diseases|June 25, 2004
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patientsMartin S King, Barry M Bernstein, Sharon L Walmsley, et al.
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The Journal of Infectious Diseases|March 28, 2003
Determining the relative efficacy of highly active antiretroviral therapyMichael Louie, Christine Hogan, Michele Di Mascio, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant TuberculosisPauline Howell, Antonio Lombardi, William Brumskine, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patientsAnn Hsu, Jeffrey Isaacson, Scott Brun, et al.
Disasters|March 8, 2014
Health care system hazard vulnerability analysis: an assessment of all public hospitals in Abu DhabiSaleh Fares, Meg Femino, Assaad Sayah, et al.
The Journal of Infectious Diseases|January 15, 2004
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trialJoseph J Eron, Judith Feinberg, Harold A Kessler, et al.
Pharmaceutical Research|October 23, 2004
Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humansGondi N Kumar, Venkata K Jayanti, Marianne K Johnson, et al.
Pageof 4